Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-06-13 DOI:10.1016/j.clinthera.2025.05.015

Erick Wesley Hedima B.Pharm, M.Pharm , John David Ohieku PharmD, MSc, PhD , Abdulrahman Nasir B.Pharm, MSc , Yahaya Mohammed Katagum B.Pharm, MSc, PhD

{"title":"Cabotegravir Plus Rilpivirine Injection for Virally Suppressed Persons with HIV-1 infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Erick Wesley Hedima B.Pharm, M.Pharm , John David Ohieku PharmD, MSc, PhD , Abdulrahman Nasir B.Pharm, MSc , Yahaya Mohammed Katagum B.Pharm, MSc, PhD","doi":"10.1016/j.clinthera.2025.05.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study evaluated the efficacy and safety of cabotegravir/rilpivirine long-acting formulation compared to oral standard of care at 48 and 52 weeks.</div></div><div><h3>Method</h3><div>We conducted an electronic search (2005–2024) across databases for articles comparing the safety and efficacy of long-acting cabotegravir/rilpivirine with oral triple ART regimens. We analyzed efficacy and safety (treatment discontinuation and adverse effects). We used proportions of participants maintaining viral suppression, experiencing adverse drug effects or discontinuing treatment due to trial regimen, risk ratios, and 95% confidence intervals for pooled estimates.</div></div><div><h3>Findings</h3><div>Five RCTs with 2215 participants were analyzed, with 1390 receiving cabotegravir/rilpivirine injections. The analysis found long-acting cabotegravir/rilpivirine as effective as oral ART for viral load suppression (RR [<em>P = 0.</em>23, 0.99 95% CI; 0.97–1.01], <em>I<sup>2</sup> =</em> 0%) up to 52 weeks. However, more adverse effects were reported with the oral treatment [RR 1.32 (95% CI; 1.12–1.54), <em>I<sup>2</sup> =</em> 56%]. Pooled reports showed a significant an increased risk of treatment withdrawal in the oral group, [RR 3.61 (95% CI; 0.87–14.98), <em>I<sup>2</sup> =</em> 53</div></div><div><h3>Implication</h3><div>Findings from this meta-analysis emphasised the efficacy and safety of Cabotegravir/rilpivirine long-acting formulation in providing long-term maintenance of viral load suppression in HIV-1 infection with a tolerable safety profile.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 8","pages":"Pages 649-656"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825001833","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study evaluated the efficacy and safety of cabotegravir/rilpivirine long-acting formulation compared to oral standard of care at 48 and 52 weeks.

Method

We conducted an electronic search (2005–2024) across databases for articles comparing the safety and efficacy of long-acting cabotegravir/rilpivirine with oral triple ART regimens. We analyzed efficacy and safety (treatment discontinuation and adverse effects). We used proportions of participants maintaining viral suppression, experiencing adverse drug effects or discontinuing treatment due to trial regimen, risk ratios, and 95% confidence intervals for pooled estimates.

Findings

Five RCTs with 2215 participants were analyzed, with 1390 receiving cabotegravir/rilpivirine injections. The analysis found long-acting cabotegravir/rilpivirine as effective as oral ART for viral load suppression (RR [P = 0.23, 0.99 95% CI; 0.97–1.01], I² = 0%) up to 52 weeks. However, more adverse effects were reported with the oral treatment [RR 1.32 (95% CI; 1.12–1.54), I² = 56%]. Pooled reports showed a significant an increased risk of treatment withdrawal in the oral group, [RR 3.61 (95% CI; 0.87–14.98), I² = 53

Implication

Findings from this meta-analysis emphasised the efficacy and safety of Cabotegravir/rilpivirine long-acting formulation in providing long-term maintenance of viral load suppression in HIV-1 infection with a tolerable safety profile.

查看原文本刊更多论文

卡波特韦加利匹韦林注射液治疗病毒抑制HIV-1感染者：随机对照试验的系统评价和荟萃分析。

目的：本研究在48周和52周时，与口服标准护理相比，评价卡博特重力韦/利匹韦林长效制剂的有效性和安全性。方法：我们在数据库中进行了电子检索（2005-2024），以比较长效卡博特重力韦/利匹韦林与口服三联抗逆转录病毒治疗方案的安全性和有效性。我们分析了疗效和安全性（停药和不良反应）。我们使用了维持病毒抑制、经历药物不良反应或因试验方案而停止治疗的参与者比例、风险比和汇总估计的95%置信区间。研究结果：共分析了5项随机对照试验，共2215名受试者，其中1390人接受了卡博特韦/利匹韦林注射。分析发现长效卡博特韦/利匹韦林在抑制病毒载量方面与口服抗逆转录病毒药物一样有效(RR [P = 0.23, 0.99 95% CI；0.97-1.01], I2 = 0%)至52周。然而，口服治疗的不良反应较多[RR 1.32 (95% CI；1.12-1.54), i2 = 56%]。综合报告显示，口服组停药风险显著增加，RR 3.61 (95% CI；含义：这项荟萃分析的结果强调了卡波特韦/利匹韦林长效制剂在HIV-1感染中长期维持病毒载量抑制的有效性和安全性，并具有可耐受的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.